These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9194479)

  • 21. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
    J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
    Levitt ML; Kassem B; Gooding WE; Miketic LM; Landreneau RJ; Ferson PF; Keenan R; Yousem SA; Lindberg CA; Trenn MR; Ponas RS; Tarasoff P; Sabatine JM; Friberg D; Whiteside TL
    Lung Cancer; 2004 Mar; 43(3):335-44. PubMed ID: 15165093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
    Ferrigno D; Buccheri G;
    Lung Cancer; 2004 Sep; 45(3):373-80. PubMed ID: 15301878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
    Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
    Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
    Neubauer MA; Reynolds CH; Joppert MG; Whitaker T; Ghaddar H; Marsland TA; Asmar L
    Clin Lung Cancer; 2005 Jan; 6(4):245-9. PubMed ID: 15694017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.
    Gridelli C; De Maio E; Barbera S; Sannicolo M; Piazza E; Piantedosi F; Brancaccio L; Morabito A; Maione P; Renda F; Signoriello G; Perrone F;
    Lung Cancer; 2008 Jul; 61(1):67-72. PubMed ID: 18683299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
    Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: a multicenter phase II study.
    Yokoyama A; Nakai Y; Yoneda S; Kurita Y; Niitani H
    Anticancer Drugs; 1997 Jul; 8(6):574-81. PubMed ID: 9300571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer.
    Shirai T; Hirose T; Noda M; Ando K; Ishida H; Hosaka T; Ozawa T; Okuda K; Ohnishi T; Ohmori T; Horichi N; Adachi M
    Lung Cancer; 2006 May; 52(2):181-7. PubMed ID: 16563558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
    Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso AM; Pegna AL; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte PF; Falcone A;
    Lung Cancer; 2005 Apr; 48(1):121-7. PubMed ID: 15777979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
    Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study.
    Einhorn LH
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-24-S8-26. PubMed ID: 9207312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
    Esteban E; Fra J; Sala M; Carrasco J; Corral N; Vieitez JM; Estrada E; Palacio I; Buesa JM; Lacave AJ
    Invest New Drugs; 2002 Aug; 20(3):317-26. PubMed ID: 12201494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer.
    Cho KH; Song YB; Choi IS; Cho EH; Choi JW; Ahn YM; Roh YH; Nam SH; Kim BS
    Jpn J Clin Oncol; 2006 Jan; 36(1):50-4. PubMed ID: 16418187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of gemcitabine in advanced non-small-cell lung cancer.
    Malayeri R; Ulsperger E; Baumgartner G; Forstner B; Aigner K; Hubner M; Kummer F; Krajnik G; Zöchbauer S; Krejcy K; Huber H; Pirker R
    Wien Klin Wochenschr; 1997 Sep; 109(17):688-91. PubMed ID: 9331958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced breast cancer: a phase II trial with gemcitabine.
    Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
    J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
    Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T; Schulz M
    J Clin Oncol; 1996 May; 14(5):1656-62. PubMed ID: 8622085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.